Kiniksa Pharmaceuticals International (KNSA) to Release Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) will likely be announcing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Kiniksa Pharmaceuticals International to post earnings of $0.37 per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA opened at $45.37 on Tuesday. The stock’s fifty day moving average is $42.29 and its two-hundred day moving average is $39.07. The firm has a market capitalization of $3.44 billion, a P/E ratio of 100.82 and a beta of 0.06. Kiniksa Pharmaceuticals International has a fifty-two week low of $18.25 and a fifty-two week high of $46.65.

Insider Buying and Selling

In related news, COO Eben Tessari sold 12,048 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $41.56, for a total transaction of $500,714.88. Following the completion of the transaction, the chief operating officer directly owned 16,666 shares in the company, valued at $692,638.96. This trade represents a 41.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Mark Ragosa sold 42,841 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $41.49, for a total transaction of $1,777,473.09. Following the sale, the chief financial officer owned 31,086 shares in the company, valued at $1,289,758.14. This trade represents a 57.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 123,823 shares of company stock valued at $5,244,967. Corporate insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds have recently added to or reduced their stakes in the business. Amundi purchased a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Kiniksa Pharmaceuticals International by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after purchasing an additional 1,002 shares in the last quarter. Millennium Management LLC increased its holdings in Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after purchasing an additional 67,452 shares during the period. Creative Planning acquired a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter valued at about $358,000. Finally, Quantbot Technologies LP acquired a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter valued at about $43,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

KNSA has been the topic of several recent research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Wedbush raised their target price on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. The Goldman Sachs Group raised their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and a consensus price target of $52.33.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.